Le Lézard
Classified in: Health
Subject: PER

ProSciento Expands Executive Team, Appoints Brian Mooney Chief Operating Officer


SAN DIEGO, Aug. 6, 2018 /PRNewswire/ -- ProSciento, Inc., a leading specialty clinical research organization (CRO) exclusively focused on NASH, diabetes, obesity and related metabolic diseases, today announced the appointment of Brian Mooney to the role of Chief Operating Officer (COO). Mooney joins ProSciento from the CRO Chiltern, a Covance company, where he served as Executive Vice President, Strategic Service Provision.

Brian Mooney appointed Chief Operating Officer of San Diego-based ProSciento, a clinical research organization focused on metabolic diseases, including diabetes, NASH and obesity.

As a member of the executive team, Mooney will lead operations for the company's CRO and clinical research unit (CRU) divisions, as well as contribute to corporate strategy and senior client relationships. Dr. Linda Morrow, ProSciento's COO since 2009, will transition to Chief Medical Officer, overseeing the company's medical and scientific teams. 

"We are thrilled to have Brian join ProSciento's executive leadership team. Brian is a prominent and respected leader in the CRO industry. His experience and expertise in implementing global expansion strategies with a keen focus on systems, processes, efficiencies and quality has led to significant successes for companies like Chiltern, Theorem and PRA," said Marcus Hompesch, MD, ProSciento's Chief Executive Officer and Chairman of the Board. "Brian also possesses a collaborative, values-driven leadership style that we consider vitally important for our corporate culture."

"ProSciento has cultivated exceptional scientific and operational expertise in clinical R&D for NASH, diabetes and obesity. This positions the company as one of the only specialty CROs providing full scope services for these therapeutic areas of significant importance to the healthcare community and drug developers," said Brian Mooney, ProSciento's newly appointed Chief Operating Officer. "I'm delighted to be part of the leadership team to support the continued growth of ProSciento and its contributions in advancing new treatments and new methodologies in these critical therapeutic areas." 

Mooney is a CRO executive with over 25 years of experience, much of it focused on global expansion of operations for mid to large CROs, including Chiltern, Theorem and Pharmaceutical Research Associates International (PRA). Prior to joining ProSciento, he served as Executive Vice President of Strategic Service Provision at Chiltern, a Covance company, where he oversaw the development and advancement of one of their core business segments. Before that, Mooney was Senior Vice President of Clinical Development and General Manager at Theorem Clinical Research (acquired by Chiltern in 2015) and oversaw the expansion and optimization of the clinical operations footprint at a time of rapid momentum for Theorem as a spin out from parent company Omnicare. Prior to his role at Theorem, over a period of 16 years, he held a succession of leadership positions at PRA, including Senior Vice President of Project Services; Vice President of Global Project Management; and Vice President of Countries Group. Over the course of his tenure at PRA, Mooney contributed significantly to the company's global expansion of clinical operations, including implementation of PRA's Global Project Management Methodology initiative and International Partners program.  He received his bachelor's degree in biology with a minor in chemistry from Trenton State College in Trenton, New Jersey.

About ProSciento, Inc.

ProSciento is a leading specialty clinical research organization (CRO) exclusively focused on NASH, diabetes, obesity and related metabolic diseases. ProSciento works with biopharma companies worldwide to support their outsourced clinical research needs with comprehensive and customized services for multinational, early development clinical trial programs. Founded in 2003, ProSciento has conducted more than 280 clinical projects for diabetes, NASH and obesity and supported the development of many approved metabolic drugs and devices on the market globally today. For more information, please visit www.prosciento.com.

SOURCE ProSciento, Inc.


These press releases may also interest you

at 11:30
The "Global Antibody Therapeutic Market: Focus on Format, Disease Area, Route of Administration, End Users, Region, and Competitive Landscape - Analysis and Forecast, 2024-2033" report has been added to  ResearchAndMarkets.com's offering. The global...

at 11:30
XtalPi Inc., a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced today the launch of its proprietary comprehensive solid...

at 11:25
Manifest Technologies, Inc., developer of an AI-powered computational neuro-imaging platform for CNS disease, today unveiled the company after completing its initial funding and partnership with a top five global pharmaceutical company. Today, over...

at 11:08
Sunwave Health, a leader in healthcare technology, proudly announces the launch of MARA, a patent-pending, innovative AI Agent designed to transform the landscape of behavioral health documentation. Since its launch on October 25, 2023, MARA has...

at 11:04
MelliCell Inc. has been awarded a U.S. National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $275,000 to conduct research and development (R&D) work on "Industrial Scale Technology for Drug Development in Mature Human...

at 11:00
Eagle Hill Consulting has earned another top workplace award, this time selected by The Washington Business Journal as a 2024 Best Places to Work in the extra-large sized company category. Eagle Hill also has earned multiple best workplace awards...



News published on and distributed by: